Richard A. Morgan

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Paul F. Robbins, Richard A. Morgan, Steven A. Feldman et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Laura A. Johnson, Richard A. Morgan, Mark E. Dudley et al. · Blood · 2009 · 1.4K citations · Full text

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Richard A. Morgan, Nachimuthu Chinnasamy, Daniel Abate‐Daga et al. · Journal of Immunotherapy · 2013 · 1.1K citations · Full text

Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation

Barbara Ensoli, Luigi Buonaguro, Giovanni Barillari et al. · Journal of Virology · 1993 · 793 citations · Full text

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran et al. · Clinical Cancer Research · 2014 · 780 citations · Full text